In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically significant reduction in the number of monthly headache days of at least moderate severity vs. placebo
The acquisition of Itacel will reinforce Roquette’s position as a major supplier to the pharmaceutical industry and a global leader in natural-based pharmaceutical excipients solutions. The combination of
Under the terms of the amended 2003 collaboration and license agreement, ImmunoGen has granted Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize the following experimental compounds
Adolescents and young adults are a critical demographic for vaccination against MenB due to inherent environmental and social risk factors such as close-quartered living and sharing behaviors. “The
The continued collaboration strengthens the ongoing partnership between the two companies, focusing on the discovery of novel treatments for tropical and neurological diseases at Eisai's 14.5 acre, state-of-the-art
Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA). SAMOS is particularly important as there is currently no validated biomarker in MPS IIIA that reflects CNS
The CRL does not require Sunovion to conduct any additional clinical studies for the approval of SUN-101/eFlow. Sunovion will work with the FDA to determine an appropriate path
This voluntary recall follows a report that a professional sample bottle containing eight tablets of BRILINTA 90mg also contained another medicine called ZURAMPIC (lesinurad) 200mg tablets which is
Changes in tau are associated with a number of diseases affecting the nervous system, including Alzheimer’s disease (AD). “Securing alliances with leading industry partners is a key part
The financing was co-led by Arix Bioscience and New Leaf Venture Partners. Mark Chin, Investment Manager at Arix, and Ron Hunt, Managing Director at New Leaf, will join
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.